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Introduction
Gabapentin [1-(aminomethyl) cyclohexaneacetic acid] is an 
antiepileptic drug structurally related to the neurotransmitter gamma-
aminobutyric acid (GABA). Gabapentin is indicated as adjunctive 
therapy in the treatment of partial seizures with and without secondary 
generalization in adults with epilepsy and for the management of 
postherpetic neuralgia [1]. Gabapentin can be actively transported 
across the brain–blood barrier and the gut via the L-system amino acid 
transporter, which recognizes L-isoleucine, L-leucine, Lphenylalanine 
and L-valine [2]. The exact mode of action of GB has not yet been clearly 
defined. Several cellular actions have been described but are likely to 
be related to multiple concentration-dependent actions resulting in 
seizure control [3]. 
Maximum plasma gabapentin concentrations (mean) are attained 
2 to 3 hours after a single oral 300 mg dose in healthy volunteers. 
Absorption kinetics of gabapentin are dose-dependent and not 
dose-proportional, Possibly due to a saturable transport system. 
Bioavailability of a single 300 mg oral dose of gabapentin is 60%, 
decreasing with Increasing dose. Gabapentin has some lipophilicity 
and readily crosses the blood-brain barrier. Its volume of distribution 
is large, estimated as 50 to 60 L in healthy volunteers. The drug is not 
bound to human plasma proteins. Elimination of gabapentin is wholly 
accountable by renal clearance. The elimination half-life of gabapentin 
is about 5 to 7 hours after a single oral dose of 200 to 400 mg. Renal 
impairment reduces drug clearance and augments plasma gabapentin 
concentrations in a linear fashion [4,5]. 
Mild adverse events, commonly fatigue, somnolence, ataxia and 
dizziness have been reported in about 75% of gabapentin recipients. 
Other events such as tremor, diplopia, nausea and vomiting were each 
experienced by < 10% of gabapentin recipients. The overall proportion 
of patients reporting adverse events during gabapentin administration 
has been calculated to be about 75%, versus 55% for placebo [4]. 
The objective of this study was to compare in healthy volunteers, 
the pharmacokinetics profiles and evaluate the bioequivalence of one 
test formulation of 400 mg capsule of gabapentin, elaborated by Arrow 
Farmacêutica S/A, Brazil (test formulation). The test formulation was 
compared to one commercial formulation of 400 mg of gabapentin 
(Neurontin®) by Pfizer, Brazil (reference formulation).
Methods
Study protocol
The study was performed in accordance with the Helsinki 
Declaration and Good Clinical Practice Guideline, and informed 
consent was obtained from participants prior to study commencement. 
The clinical part of the study was condueted at Scentryphar Clinical 
Research (Campinas City, São Paulo, Brazil) and the bioanalytical 
part at Nucleus of Bioequivalence and Clinical Research/NUBEC (São 
Paulo, Brazil).
Subjects
Twenty six healthy volunteers of both sexes (13 males and 13 
females) who were between the ages of 20 and 45 (mean ± SEM: 28.7 
± 7.4 years), who had heights between 150.0 cm and 180.0 cm (170.0 ± 
0.1 cm), and who weighed between 52.0 kg and 87.8 kg (65.7 ± 9.8 kg) 
and within 15% of their ideal body weight were enrolled in the study. 
Subjects were judged eligible for enrolment in this study if they were 
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Abstract
The study was performed to compare the bioavailability of two gabapentin 400 mg capsule formulation 
(Gabapentin from Arrow Farmacêutica S/A as test formulation and Neurontin® from Pfizer, Brazil, as reference 
formulation) in 26 volunteers of both sexes. The study was conducted open with randomized two period crossover 
design and a one week wash out period. Plasma samples were obtained over a 48 hour interval. The gabapentin 
was analyzed by LC/MS/MS, in the presence of pracetamole as internal standard. With plasma concentration vs. 
time curves, data obtained from this metabolite, the following pharmacokinetics parameters were obtained: AUC0-t, 
AUC0-inf and Cmax. Geometric mean of gabapentin/Neurontin
® 400 mg individual percent ratio was 100.58% AUC0-t, 
101.35% for AUC0-inf and 97.76% for Cmax. The 90% confidence intervals were 92.00 – 109.95%, 93.00 – 110.44%, 
88.41 – 108.10%, respectively. Since the 90% confidence intervals for Cmax, AUC0-t and AUC0 -inf were within the 80 
– 125% interval proposed by Food and Drug Administration, it was concluded that gabapentin 400 mg capsule was 
bioequivalent to Neurontin® 400 mg capsule according to both the rate and extent of absorption.
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in compliance with all the inclusion and exclusion criteria described 
in the protocol. 
All the subjects provided written informed consent to participate 
after explaining the nature and purpose of the study. The study 
protocol was approved by the M.M. Assert Serviços Médicos S/A Ltda 
with the ethical principles described in the Declaration of Helsinki, 
guidelines for International Conference on Harmonization-Good 
clinical practices (ICH-GCP).
All volunteers were healthy as assessed by physical examination, 
ECG, and the following laboratory tests: blood glucose, urea, creatinine, 
AST, ALT, alkaline phosphatase, Gamma GT, total bilirrubin, 
albumin and total protein, triglycerides, total cholesterol, hemoglobin, 
hematocrit, total and differential white cell counts and routine urine. 
All subjects were negative for HIV, HBV (except for serological scare) 
and HCV.
Drug products
The test formulation employed was Gabapentin 400 mg capsule 
(lot number AE87) and the reference formulation was: Neurontin® 400 
mg capsule (lot number 835F4C).
Study design
The study was performed to compare the bioavailability of two 
gabapentin 400 mg capsule formulation (Gabapentin from Arrow 
Farmacêutica S/A as test formulation and Neurontin® from Pfizer, 
Brazil, as reference formulation) under fasting conditions. 
The study was conducted in an open randomized 2 period 
crossover balanced design with a 1 week wash out period between the 
doses. During each period, the volunteers were hospitalized at 8:00 pm 
having already had a normal evening meal, and after an overnight fast 
they received at 7:00 am a single 400 mg capsule gabapentin dose of 
either formulation. Water (200 mL) was given immediately after drug 
administration. All volunteers were then fasted 05 hours following the 
drug administration, after which a standard lunch was consumed and 
an evening meal was provided 10 hours after dosing. No other food 
was permitted during the “in-house” period. Liquid consumption 
was permitted ad libitum after lunch but xanthine-containing drinks 
including tea, coffee and cola were avoided. Systolic and Diastolic 
arterial pressure, heart rate and temperature were recorded just before 
and hourly after drug administration.
Blood samples (08 mL) from a suitable antecubital vein were 
collected into heparin containing tubes before and 0.20, 0.40, 1.00, 
1.20, 1.40, 2.00, 2.20, 2.40, 3.00, 3.30, 4.00, 5.00, 6.00, 8.00, 10.0, 12.0, 
24.0, 36.0, 48.0 hours after administration of each gabapentin 400 mg 
capsule.
Drug analysis
Blood samples were cooled in an bath and centrifuged at 3.000 
rpm for at least 10 min at approximately 4°C. At least 3mL of plasma 
were dispensed into polypropylene tubes. Sample tubes were frozen at 
–20°C, and maintained to that temperature until analysis. All samples 
from a single volunteer were analyzed on the same day in order to 
avoid interassay variation.
Plasma concentrations of gabapentin was determined by the 
HPLC coupled with tandem mass spectrometry (LC/MS/MS), using 
acetaminophen as internal standard (IS). Plasma samples were 
deproteinized with acetonitrile. Briefly, 20 μL of IS solution (25 μg/mL) 
and 200 μL of acetonitrile were added to a 200 μL aliquot of human 
plasma, vortex-mixed for 40 s and 200 μL of supernatant  were added 
to a 200 μL of mobile phase. An aliquot of 10 μL of the supernatant was 
injected into the LC/MS/MS system. 
The analytical column was a Luna–C8, 150 x 4,6 mm, 5μ 
(Phenomenex). The mobile phase used was a mixture of methanol and 
water (30:70 v/v), containing 10 mM acetic acid. The chromatographic 
run time lasted 4.0 minutes with flow rate of 1.0 mL/min, in ambient 
temperature.
Method validation
Quantitation was based on determination of relationship between 
gabapentin peaks areas and I.S. peaks areas. Selectivity was evaluated 
by extracting plasma samples of plasma from six different volunteers, 
including a lipemic and hemolysed plasma. Recoveries of gabapentin 
at the three QC concentrations and I.S. were determined by comparing 
peak areas of spiked plasma samples with the peak area in solutions 
prepared with the same nominal concentration. For precision (as 
relative standard deviation, R.S.D.) and accuracy (as relative error, 
R.E.) studies, samples were prepared at three QC and were analysed 
in the same day (intraday precision and accuracy), and analysed in 3 
consecutive days (inter-day precision and accuracy). 
The validated method show a Lower limit of quantification of 50 
ng/mL and linearity > 0, 98.
The intra-day accuracy and precision of the quality control samples 
ranged from 91.63-100.67% and 1.14-4.73%. The inter-day accuracy 
and precision of the quality control samples ranged from 99.83-
102.03% and 0.69-7.99%. Similar accuracy and precision values were 
observed during the study sample analysis.
The recovery of gabapentin was greater than 62.87%. No matrix 
effect on quantification was observed. The stability of gabapentin was 
also evaluated in post-extracted samples kept in the autosampler at 
room temperature (23°C) for 24 h, as well as in plasma samples kept 
at -20°C for 89 days and after being submitted to 3 freeze-thawing 
cycles (24 h each cycle). All samples described above were compared to 
freshly prepared gabapentin samples at the same concentration level. 
The method was validated according to ANVISA’s (National Health 
Surveillance Agency of Brazilian Government) criteria and used to 
determine the concentration of gabapentin in volunteers’ plasma.
Pharmacokinetic analysis and statistical analysis
The first-order terminal elimination rate constant (Ke) was 
estimated by linear regression from the points describing the elimination 
phase on a log-linear plot, using the software SAS® Institute (Version 
9.1.3). Elimination half-life (T½) was derived from this rate constant 
(T½ = ln (2)/Ke). The maximum observed plasma concentration (Cmax) 
and the time taken to achieve this concentration (Tmax) were obtained 
directly from the curves. The areas under the gabapentin metabolite 
plasma concentration versus time curves from 0 to 48 hours (AUC0-48h) 
were calculated by applying the linear trapezoidal rule. Extrapolation of 
these areas to infinity (AUC0-∞) was done by adding the value C48/Ke to 
the calculated AUC0-48h (where C48=plasma concentration calculated 
from the log-linear regression equation obtained for the estimation of 
Ke 48 hours after dose).
The bioequivalence between both formulations was assessed by 
calculating individual Cmax, AUC0-48h, AUC0-∞ and Cmax/AUC0-48h ratios 
(test/reference) together with their mean and 90% confidence intervals 
(CI) after log transformation of the data. The inclusion of the 90% CI 
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for the ratio in the 80% to 125% range was analyzed by nonparametric 
(SAS® Institute Version 9.1.3) and parametric (ANOVA) methods.
Results
Tolerability analysis
Gabapentin was well tolerated at the administered dose. All the 
biochemical parameters did not any clinical relevant alterations. No 
adverse effects serious were either reported or observed.
Pharmacokinetic and statistical analysis
The number of volunteers must always ensure enough statistical 
power to ensure the reliability of the results of the bioequivalence 
study. The number of volunteers in the study in question was calculated 
using the coefficient of variation and statistical power available in 
the literature. The study protocol established sufficient number of 
volunteers providing potential “dropouts”.
The mean (± SD) plasma concentration time profile of the 2 
formulations, shown in Figure 1, was similar and superimposable. 
Central and dispersion measures for all pharmacokinetic 
parameters for both formulations are shown in Table 1, and Table 2. 
Table 3 presents the ratios and the respective confidence intervals for 
bioequivalence analysis.
Discussion
Several analytical methods have been reported for the determination 
of gabapentin in human plasma and biological samples. The methods 
are based on high-performance liquid chromatography (HPLC) with 
UV [6,7] or fluorescence detection [8-13], capillary electrophoresis 
(CE) [14,15], gas chromatography (GC) with flame ionization [16] or 
mass spectrometry (MS) [17-19], and liquid chromatography–tandem 
mass spectrometry (LC–MS–MS) [20-25]. The HPLC and CE methods 
are time-consuming because they require derivatization of gabapentin 
to produce a detectable chromophore. The GC methods also require 
derivatization of gabapentin to improve volatility and avoid column 
interactions. For routine analysis, derivatization step increases 
the time of sample preparation and cost. LC–MS–MS is currently 
considered the method of choice for determining gabapentin levels in 
biological samples because the drug can be directly detected without 
derivatization, thus making sample preparation time shorter. 
The purpose of the present study was to develop and validate an 
LC–MS–MS method with simple sample preparation to determine 
gabapentin concentration in human plasma and to apply it to a 
bioequivalence study of 400 mg gabapentin capsule in 26 healthy 
volunteers. A rapid, sensitive and reliable LC/MS/MS method for the 
determination of gabapentin in human plasma has been successfully 
developed and validated using deproteinized extraction as sample 
preparation procedure. This assay method demonstrated acceptable 
sensitivity (LLOQ: 50 ng/mL), precision, accuracy, selectivity, recovery 
and stability, and less absolute and relative matrix effect. The validated 
method was successfully applied to assay human plasma samples from 
the bioequivalence study of gabapentin. 
Figure 1: Figure 1: Gabapentin plasma means concentration versus time 
profile obtained after the single oral administration of 400mg of Neurontin® 
formulation.
TEST REFERENCE
Parameter (unit) Means (Median) Standard Deviation Means (Median) Standard Deviation (Amplitude)
AUC0-t (ng.h/mL) 26754.62 9051.43 27701.48 12103.08
AUC0-inf (ng.h/mL) 27794.60 897110 28543.25 11960.75
Cmax, (ng.h/mL) 3020.35 949.72 3241.93 1398 .00
Tmax (median/amp) (h) 3.25 5.00 3.00 5.00
Kel (1/h) 0.13 0.04 0.14 0.03
T½, (median/amp) (h) 5.31 7.23 5.49 5.32
Table 1: Mean pharmacokinetic parameters of Gabapentin of test and reference formulation.
TEST REFERENCE
Parameter (unit) Geometric Mean Geometric Mean
AUC0-t (ng.h/mL) 24942.67 24799.92
AUC0-inf (ng.h/mL) 26157.87 2581 0.51
Cmax, (ng.h/mL) 2853.74 2919.08
Table 2: Geometric mean pharmacokinetic parameters of Gabapentin of test and reference formulation.
Parameter Ratio T/R (%) Lower Limit (%) Upper Limit (%) Power (%) Coefficient of Variation (%)
AUC0-t (ng.h/mL) 100 .58 92.00 100 95 0.9878 0.1894
AUC0-inf (ng.h/mL) 1 01.35 93.00 110.44 0.9005 0.1825
Cmax, (ng.h/mL) 97.76 88.41 108.10 0.9450 0.2143
Tmax (dif) (h) 0.17 0.00 0.67 - -
Table 3: Ratios mkeans and the 90% geometric confidence interval of test and reference formulation.
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The bioavailability of a pharmaceutical form refers to the extent 
and speed of absorption of the active principle in contained it. Two 
pharmaceutical forms are said bioequivalent when, to be administered 
to the same individual, in the same experimental conditions and 
at the same dose, showed no significant differences in relation to 
bioavailability. In this study two formulations of gabapentin had been 
evaluated. The mean ratio of parameters Cmax and AUC0-t and 90% 
confidence intervals of correspondents were calculated to determine 
the bioequivalence. 
The AUC0-t and AUC0-∞ are both recognized as an uncontaminated 
measurement of the extent of absorption. The present study showed 
that 90% CI of mean AUC0-t and AUC0-∞ (after log-transformation 
of individual ratios) were included into the bioequivalence range 
(80-125%), consequently, the two formulations of gabapentin are 
equivalent for the extend of absorption.
The statistical comparison of Cmax, AUC0-t and AUC0-∞ clearly 
indicated no significant difference in the two formulations of 
gabapentin 400 mg capsule. 90% confidence intervals for the mean ratio 
(T/R) of Cmax, AUC0-t and AUC0-∞ were entirely within the US Food and 
Drug Administration acceptance range. Based on the pharmacokinetic 
and statistical results of this study, we can conclude that gabapentin 
400 mg capsule (Arrow Farmacêutica S/A, Brazil) is bioequivalent 
to Neurontin® 400 mg capsule (Pfizer, Brazil), and that then the test 
product can be considered interchangeable in medical practice.
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